Scleroderma

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
NRP2, Research, Safety, SAN, Neuropilin, PST, D, BLA, Sarcoidosis, ILD, Scleroderma, International, Investment, Systemic scleroderma, ERS, Clinical trial, Patient, European Respiratory Society, DSMB, Rheumatoid arthritis, ATyr Pharma, American College, American College of Rheumatology, Small RNA, The Journal, Frontiers, Skin, ACR, Poster, Biologics license application, Pharmaceutical industry, Pharmacology, Kyorin

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.

Key Points: 
  • Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments.
  • SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company expects to complete enrollment in the study early in the second quarter of 2024.
  • G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2023.

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Health, Pharmaceutical, Research, Antibody, Immune system, Non-Hodgkin lymphoma, Therapy, Lymphoid leukemia, Loncastuximab tesirine, Scleroderma, CRS, JW, IND, Tafasitamab, Tisagenlecleucel, B-cell lymphoma, Patient, Systemic scleroderma, CD19, Blinatumomab, FDA, Lupus, Acute leukemia, SLE, Chronic lymphocytic leukemia, Novartis, Sjögren syndrome, Neurotoxicity, Quality of life, NHL, Fast Track, ALL, Cytokine release syndrome, CLL, Vaccine, Pharmaceutical industry, Amgen

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Contract research organization, Business analyst, Scleroderma, Benaroya Research Institute, Clinical trial, Administration, Research and development, Inflammation, Strategic planning, Interleukin 7, Alopecia areata, Research fellow, G&A, Ulcerative colitis, Thymic stromal lymphopoietin, Atopic dermatitis, TSLP, R, CMC, Chronic obstructive pulmonary disease, IL-7, Hidradenitis suppurativa, Asthma, Allergy, Pharmaceutical industry, Cryptocurrency

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.
  • "In the third quarter, Zura Bio made significant progress in its strategic planning across various key areas, including Clinical, Regulatory, CMC, and Translational Science.
  • This progress positions Zura Bio for clinical trial readiness in 2024," stated Dr. Someit Sidhu, Chief Executive Officer of Zura Bio.
  • Zura Bio anticipates that its cash and cash equivalents are sufficient to fund its planned operations into 2026.

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
Monday, November 13, 2023
Agriculture, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Mental Health, Cannabis, Clinical Trials, Composition, Shingles, Fibromyalgia, Cannabinoid, Research, NYSE, Treating, Scleroderma, IND, Epilepsy, Administration, Patient, IGC, Intelligence, Canadian Intellectual Property Office, Agitation, Dementia, LMP, Psoriatic arthritis, Human, Pain, Patent, Pharmaceutical industry, Cryptocurrency

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).
  • Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000.
  • In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year’s six-month period.
  • The Company continues to drive progress with ten sites in the United States and Canada, currently conducting the trial.

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Retrieved on: 
Thursday, November 16, 2023
Fibroblast, Parallel Walk Test, Endothelium, Therapy, Pathology, Scleroderma, Systemic scleroderma, CMMB, Axis, Risk, Pulmonary hypertension, Patient, Nature, American College of Rheumatology, Autoimmune disease, Orthostatic hypertension, American College, CCR3, Malignancy, CCL24, Sclerosis, Communication, Doctor of Philosophy, PAH, Skin, ACR, TEL, Pharmaceutical industry, Disease

TEL AVIV, Israel, Nov. 16, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported on its poster presentation at the American College of Rheumatology (ACR) Convergence 2023 conference. The study, which was conducted by Chemomab researchers working in collaboration with academic scientists, analyzed serum samples and clinical data from patients with systemic sclerosis (SSc) to assess the effect of the soluble protein CCL24 on the pathogenesis of SSc and its association with key aspects of SSc pathology. Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes. CM-101 has been studied extensively in preclinical and patient models of SSc. Chemomab has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.

Key Points: 
  • Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes.
  • Chemomab has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.
  • Systemic sclerosis is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs.
  • Using cell-based assays, the researchers showed that CCL24, alongside factors present in the SSc microenvironment, enhances the EndMT process.

HSS Presents New Reproductive Health Research at the ACR Convergence 2023

Retrieved on: 
Tuesday, November 14, 2023
Knowledge, Woman, Cervical cancer, Contraindication, Patient, Rheumatoid arthritis, Documentation, SLE, Infertility, Diagnosis, Rheumatology, Rheumatism, Fertility, Prevalence, Menopause, Vaccination, Cryopreservation, Flare, DSM-IV codes, Birth, Connective tissue, Hospital for Special Surgery, Doctor of Public Health, Female, Fetus, Smoking, Senior counsel, RD, SAN, Menstrual cycle, Weill Cornell Medicine, Immunosuppression, Risk, History, Hysterectomy, Inflammatory arthritis, Lupus, HSS, PAP, Fertilisation, OOC, Research, Human papillomavirus infection, Ageing, Scleroderma, Systemic scleroderma, Vaccine, American College, American College of Rheumatology, COVID-19, Fertility preservation, MPH, ACR, HPV, Hospital, Birth control, Nursing, Food delivery, MD

Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.

Key Points: 
  • Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.
  • This study surveyed women of reproductive age with systemic rheumatic disease about their use of contraceptives.
  • Data were collected on 249 women with reproductive capacity, including 147 with inflammatory arthritis and 102 with lupus-like disorders.
  • This study used data from the electronic health record of patients diagnosed with a rheumatic disease in adolescence, seen at HSS, to look at factors associated with HPV vaccination.

Kyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on Receiving the 2023 ACR Distinguished Clinical Investigator Award

Retrieved on: 
Saturday, November 11, 2023
Medicine, Research, Epidemiology, Therapy, University, Scleroderma, Patient, CD19, American College of Rheumatology, American College, Rheumatology, Lupus nephritis, ACR, Vasculitis, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 11, 2023 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, congratulates Peter A. Merkel, M.D., M.P.H., a member of the Kyverna's scientific advisory board, on receiving the 2023 ACR Distinguished Clinical Investigator Award by the American College of Rheumatology (ACR). The recognition is given annually to a member who exhibits outstanding contributions to the field of rheumatology.

Key Points: 
  • The recognition is given annually to a member who exhibits outstanding contributions to the field of rheumatology.
  • "All of us at Kyverna celebrate this well-deserved recognition of Dr. Merkel's impact in the field of rheumatology," said Peter Maag, Ph.D., chief executive officer of Kyverna.
  • Dr. Merkel's research focuses on clinical trial design and conduct, outcome-measure development, clinical epidemiology, genetic epidemiology, and biomarker discovery.
  • Dr. Merkel has been a Kyverna Advisory Board member since 2022.

Cool Comedy • Hot Cuisine, A Tribute to Bob Saget, Raises More Than $1.2M for Scleroderma Research Foundation as Part of the 19th Annual New York Comedy Festival

Retrieved on: 
Friday, November 10, 2023
Carolines, Research, SAN, Scleroderma Research Foundation, Scleroderma, Disease, Patient, Human, Heart, Music, A Long December, CBS, New York Comedy Festival, MD, Crow, Laughter, Skin, Name, SRF, Fibrosis, Entertainment, Film industry, Saget

SAN FRANCISCO, Nov. 10, 2023 /PRNewswire/ -- Last night, the Scleroderma Research Foundation (SRF) presented its annual Cool Comedy • Hot Cuisine, a tribute to Bob Saget, raising more than $1.2M for the SRF as part of the 19th Annual New York Comedy Festival.

Key Points: 
  • SAN FRANCISCO, Nov. 10, 2023 /PRNewswire/ -- Last night, the Scleroderma Research Foundation (SRF) presented its annual Cool Comedy • Hot Cuisine, a tribute to Bob Saget, raising more than $1.2M for the SRF as part of the 19th Annual New York Comedy Festival.
  • Hirsch was a dear friend of Bob Saget and had a long and generous history of helping him to raise funds and awareness for scleroderma research.
  • I'm very grateful to her and she does a lot of work for the Scleroderma Research Foundation," adds Jeff Ross.
  • The SRF funds and facilitates the most promising, highest-quality research aimed at improved therapies and, ultimately, a cure for scleroderma.

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
SLE, GMG, FDA, Systemic scleroderma, Research, CAR, CART, Report, American College, IND, Syndrome, Cyclophosphamide, MPV, MuSK protein, Dermatomyositis, Food, Nidec ASI, Myositis, Oxford, CD19, Molecular Therapy, Pemphigus, Good manufacturing practice, MG, Lupus, Conference, University, DM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, American College of Rheumatology, Development, Wuxi, San Diego Convention Center, Disease, Scleroderma, Immunoglobulin therapy, GMP, Autoimmunity, Investment, Patient, ACR, Investigational New Drug, Pharmaceutical industry, Vaccine, Nightclub, Cryptocurrency, Cabaletta, Limited

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • In November 2023, Cabaletta announced the Company’s fourth IND application for CABA-201 was cleared by the FDA for a Phase 1/2 study in patients with generalized myasthenia gravis (gMG).
  • Cabaletta will present new preclinical data for CABA-201 in a poster presentation and Cabaletta Bio Scientific Advisory Board members Carl June, M.D., and Georg Schett, M.D.
  • Cabaletta plans to participate in the following upcoming investor conferences:
    Stifel 2023 Healthcare Conference, which is being held from November 14-15, 2023 in New York, NY.
  • As of September 30, 2023, Cabaletta had cash, cash equivalents and short-term investments of $164.4 million, compared to $106.5 million as of December 31, 2022.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Allergy, Neoplasm, FDA, Research, Psoriasis, Kidney cancer, NSCLC, Scientific Reports, Carcinoma, Pulmonary fibrosis, Nivolumab, Asilomar International Conference on Climate Intervention Technologies, T helper cell, Preprint, Scleroderma, PTCL, Pembrolizumab, Head, 65th Infantry Regiment, BioRxiv, Cytokine, Time management, Ipilimumab, RCC, ITK, Society, ASH, Clinical trial, Science, Asthma, Cancer, Webcast, Lung cancer, Autoimmunity, Total, Conference call, Patient, Lymphoma, Communications satellite, Pharmaceutical industry, Vaccine, Cryptocurrency, T helper 17 cell, Corvus, Conference

BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • The paper highlights the potential of selective ITK inhibition for the treatment of cancers and helps to confirm preclinical and clinical results generated by Corvus.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the third quarter 2023 financial results.